Singapore markets closed
  • Straits Times Index

    3,208.86
    -8.55 (-0.27%)
     
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • Dow

    33,507.50
    -158.80 (-0.47%)
     
  • Nasdaq

    13,219.32
    +18.02 (+0.14%)
     
  • Bitcoin USD

    28,326.71
    +1,127.29 (+4.14%)
     
  • CMC Crypto 200

    607.49
    +28.73 (+4.96%)
     
  • FTSE 100

    7,578.44
    -29.64 (-0.39%)
     
  • Gold

    1,851.60
    -14.50 (-0.78%)
     
  • Crude Oil

    91.64
    +0.85 (+0.94%)
     
  • 10-Yr Bond

    4.5730
    0.0000 (0.00%)
     
  • Nikkei

    31,759.88
    -97.72 (-0.31%)
     
  • Hang Seng

    17,809.66
    +436.66 (+2.51%)
     
  • FTSE Bursa Malaysia

    1,418.76
    -5.41 (-0.38%)
     
  • Jakarta Composite Index

    6,961.46
    +21.57 (+0.31%)
     
  • PSE Index

    6,304.53
    -16.71 (-0.26%)
     

Which Is the Better Buy: Vertex or Invitae?

Which Is the Better Buy: Vertex or Invitae?

Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%. Looking at these two biotech stocks from a long-term perspective, is Invitae now the better buy? Or is Vertex's strong run this year likely to extend into 2023?